MET and sarcoma: Knock down of the hepatocyte growth factor receptor, c-MET, significantly enhanced the lethality of [602 + doxorubicin] in sarcoma cells, arguing that the immediate-early activation of this receptor tyrosine kinase was a compensatory survival signal (Supplementary Figure 5).